目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 PRECISION DIAGNOSTICS MARKET
2.2.2 PRECISION MEDICINE MARKET
2.2.3 INSIGHTS FROM PRIMARY SOURCES
2.3 TOP-DOWN APPROACH
2.3.1 PRECISION DIAGNOSTICS MARKET
2.3.2 PRECISION MEDICINE MARKET
2.4 GROWTH FORECAST MODEL
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
4.2 PRECISION MEDICINE MARKET OVERVIEW
4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023
4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029
4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023
4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023
4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029
4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies
5.2.1.2 Rise in direct-to-consumer testing
5.2.1.3 Growing integration of artificial intelligence and machine learning
5.2.2 RESTRAINTS
5.2.2.1 High cost of precision healthcare
5.2.3 OPPORTUNITIES
5.2.3.1 Expanding applications of precision healthcare
5.2.3.2 Growing adoption of wearable devices
5.2.4 CHALLENGES
5.2.4.1 Complex regulatory approval landscape
5.2.4.2 Big data management and integration issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.5.1 PRECISION DIAGNOSTICS MARKET
5.5.2 PRECISION MEDICINE MARKET
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PRECISION DIAGNOSTICS MARKET
5.6.2 PRECISION MEDICINE MARKET
5.7 ECOSYSTEM ANALYSIS
5.8 PIPELINE ANALYSIS
5.9 DIAGNOSTIC PRODUCT ANALYSIS
5.10 INVESTMENT/FUNDING ACTIVITY
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Next-generation sequencing
5.11.1.2 Immunohistochemistry
5.11.1.3 Liquid biopsy
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Single-cell analysis
5.11.2.2 AI and ML integration
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Theranostics
5.11.3.2 Imaging technologies
5.12 PATENT ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 IMPORT DATA
5.13.2 EXPORT DATA
5.14 KEY CONFERENCES AND EVENTS, 2025-2026
5.15 REGULATORY LANDSCAPE
5.15.1 REGULATORY ANALYSIS
5.15.1.1 North America
5.15.1.2 Europe
5.15.1.3 Asia Pacific
5.15.1.4 Rest of the World
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.16 PORTER'S FIVE FORCES ANALYSIS
5.16.1 PRECISION DIAGNOSTICS MARKET
5.16.1.1 Threat of new entrants
5.16.1.2 Threat of substitutes
5.16.1.3 Bargaining power of buyers
5.16.1.4 Bargaining power of suppliers
5.16.1.5 Intensity of competitive rivalry
5.16.2 PRECISION MEDICINE MARKET
5.16.2.1 Threat of new entrants
5.16.2.2 Threat of substitutes
5.16.2.3 Bargaining power of buyers
5.16.2.4 Bargaining power of suppliers
5.16.2.5 Intensity of competitive rivalry
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET
5.18.1 INTRODUCTION
5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES
5.18.3 AI USE CASES
5.18.4 KEY COMPANIES IMPLEMENTING AI
5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM

6 PRECISION DIAGNOSTICS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 GENETIC TESTING
6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH
6.3 DTC TESTING
6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH
6.4 OTHER TYPES

7 PRECISION DIAGNOSTICS MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH
7.3 NEUROLOGY
7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET
7.4 IMMUNOLOGY
7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET
7.5 OTHER DIAGNOSTIC INDICATIONS

8 PRECISION DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 CLINICAL LABORATORIES
8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH
8.3 HOSPITALS
8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET
8.4 HOME CARE SETTINGS
8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH

9 PRECISION MEDICINE MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 MONOCLONAL ANTIBODIES
9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH
9.3 INHIBITOR DRUGS
9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH
9.4 CELL & GENE THERAPIES
9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET
9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS
9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH
9.6 OTHER PRODUCTS

10 PRECISION MEDICINE MARKET, BY INDICATION
10.1 INTRODUCTION
10.2 ONCOLOGY
10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET
10.3 RARE DISEASES
10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH
10.4 INFECTIOUS DISEASES
10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET
10.5 HEMATOLOGICAL DISORDERS
10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH
10.6 OTHER MEDICINE INDICATIONS

11 PRECISION MEDICINE MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET
11.3 HOME CARE SETTINGS
11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH

12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth
12.2.3 CANADA
12.2.3.1 Growing cancer burden to support growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market
12.3.3 UK
12.3.3.1 Favorable government support to expedite growth
12.3.4 FRANCE
12.3.4.1 Growing preference for personalized medicine to fuel market
12.3.5 ITALY
12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.
12.3.6 SPAIN
12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Growing regulatory approvals for precision medicines to boost market
12.4.3 JAPAN
12.4.3.1 Increasing availability of health insurance to encourage growth
12.4.4 INDIA
12.4.4.1 Rising burden of chronic diseases to promote growth
12.4.5 AUSTRALIA
12.4.5.1 Booming research & development investments to spur growth
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market
12.5.3 MEXICO
12.5.3.1 Booming biopharmaceutical sector to contribute to growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024
13.2.1 PRECISION DIAGNOSTICS MARKET
13.2.2 PRECISION MEDICINE MARKET
13.3 REVENUE ANALYSIS, 2021-2023
13.3.1 PRECISION DIAGNOSTICS MARKET
13.3.2 PRECISION MEDICINE MARKET
13.4 MARKET SHARE ANALYSIS, 2023
13.4.1 PRECISION DIAGNOSTICS MARKET
13.4.2 PRECISION MEDICINE MARKET
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.5.1 PRECISION DIAGNOSTICS MARKET
13.5.1.1 Stars
13.5.1.2 Emerging leaders
13.5.1.3 Pervasive players
13.5.1.4 Participants
13.5.1.5 Company footprint: Key players, 2023
13.5.1.5.1 Company footprint
13.5.1.5.2 Region footprint
13.5.1.5.3 Type footprint
13.5.1.5.4 Indication footprint
13.5.2 PRECISION MEDICINE MARKET
13.5.2.1 Stars
13.5.2.2 Emerging leaders
13.5.2.3 Pervasive players
13.5.2.4 Participants
13.5.2.5 Company footprint: Key players, 2023
13.5.2.5.1 Company footprint
13.5.2.5.2 Region footprint
13.5.2.5.3 Product footprint
13.5.2.5.4 Indication footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PRECISION DIAGNOSTICS MARKET
13.6.1.1 Progressive companies
13.6.1.2 Responsive companies
13.6.1.3 Dynamic companies
13.6.1.4 Starting blocks
13.6.1.5 Competitive benchmarking
13.6.1.5.1 Detailed list of key startups/SMES
13.6.1.5.2 Competitive benchmarking of startups/SMEs
13.6.2 PRECISION MEDICINE MARKET
13.6.2.1 Progressive companies
13.6.2.2 Responsive companies
13.6.2.3 Dynamic companies
13.6.2.4 Starting blocks
13.6.2.5 Competitive benchmarking
13.6.2.5.1 Detailed list of key startups/SMES
13.6.2.5.2 Competitive benchmarking of startups/SMEs
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.7.1 PRECISION DIAGNOSTICS MARKET
13.7.2 PRECISION MEDICINE MARKET
13.8 BRAND/PRODUCT COMPARISON
13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS
13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES AND APPROVALS
13.10.2 DEALS
13.10.3 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches and approvals
14.1.1.3.2 Deals
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 ABBOTT
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 GUARDANT HEALTH
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 EXACT SCIENCES CORPORATION
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 QIAGEN
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 MYRIAD GENETICS, INC.
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Other developments
14.1.8 NATERA, INC.
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches and approvals
14.1.8.3.2 Deals
14.1.9 ILLUMINA, INC.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.9.3.2 Deals
14.1.10 THERMO FISHER SCIENTIFIC INC.
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.11 DANAHER
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches and approvals
14.1.11.3.2 Deals
14.1.12 23ANDME, INC.
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 MERCK & CO., INC.
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.14 GILEAD SCIENCES, INC.
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Product launches and approvals
14.1.14.3.2 Deals
14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Product launches and approvals
14.1.16 BRISTOL-MYERS SQUIBB COMPANY
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Product launches and approvals
14.1.16.3.2 Deals
14.1.17 NOVARTIS AG
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.17.3 Recent developments
14.1.17.3.1 Product launches and approvals
14.1.17.3.2 Deals
14.1.18 ASTRAZENECA
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.18.3.2 Deals
14.1.19 ABBVIE INC.
14.1.19.1 Business overview
14.1.19.2 Products offered
14.1.19.3 Recent developments
14.1.19.3.1 Product launches and approvals
14.1.19.3.2 Deals
14.1.19.3.3 Expansions
14.1.20 LILLY
14.1.20.1 Business overview
14.1.20.2 Products offered
14.1.20.3 Recent developments
14.1.20.3.1 Product launches and approvals
14.1.20.3.2 Deals
14.1.21 PFIZER INC.
14.1.21.1 Business overview
14.1.21.2 Products offered
14.1.21.3 Recent developments
14.1.21.3.1 Product launches and approvals
14.1.21.3.2 Deals
14.1.22 SAREPTA THERAPEUTICS, INC.
14.1.22.1 Business overview
14.1.22.2 Products offered
14.1.22.3 Recent developments
14.1.22.3.1 Product launches and approvals
14.1.22.3.2 Deals
14.1.23 VERTEX PHARMACEUTICALS INCORPORATED
14.1.23.1 Business overview
14.1.23.2 Products offered
14.1.23.3 Recent developments
14.1.23.3.1 Product launches and approvals
14.1.23.3.2 Deals
14.1.24 GSK PLC.
14.1.24.1 Business overview
14.1.24.2 Products offered
14.1.24.3 Recent developments
14.1.24.3.1 Product launches and approvals
14.1.24.3.2 Deals
14.2 OTHER PLAYERS
14.2.1 SANOFI
14.2.2 JOHNSON & JOHNSON SERVICES, INC.
14.2.3 AMGEN INC.
14.2.4 MERCK KGAA
14.2.5 ALNYLAM PHARMACEUTICALS, INC.
14.2.6 INCYTE
14.2.7 ARUP LABORATORIES
14.2.8 DEVYSER
14.2.9 DIASORIN S.P.A.
14.2.10 TEMPUS
14.2.11 PILLAR BIOSCIENCES INC.
14.2.12 INVIVOSCRIBE, INC.
14.2.13 NEUROCODE
14.2.14 C2N DIAGNOSTICS
14.2.15 TRINITY BIOTECH
14.2.16 AMOY DIAGNOSTICS CO., LTD.

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS